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Succinic semialdehyde reductase (SSR) that catalyzes the reduction of succinic semi-
aldehyde (SSA) to y-hydroxybutyrate (GHB) has been identified as one of the NADPH-
dependent aldehyde reductases. Reduction of SSA to GHB strongly supports the proposal 
that GHB biosynthesis may be an important step in the GABA shunt. It is phar-
macologically significant in anesthesia, evoking the state of sleep, and an increase in brain 
dopamine level. Monoclonal antibodies against bovine brain succinic semialdehyde reduc-
tase were produced. Using the anti-succinic semialdehyde reductase antibodies, we in-
vestigated the distribution of brain succinic semialdehyde reductase in rat brain. The 
brain tissues were sectioned with a basis on the rat brain atlas of Paxinos and were stain-
ed by the immunoperoxidase staining method using monoclonal antibodies. In the section 
of the frontal lobe, immunoreactive cells were observed in the lateral septal area, the ven-
tral paUidum, which belongs to the substantia innominata. We could observe im-
munoreactive cells in the reticular thalamic nucleus, which is closely related with 'sleeping', 
the basal nuclei of Meynert, which is associated with Alzheimer's disease, and hy-
pothalamic nuclei. Immunoreactive cells were also shown in raphe nuclei or the reticular 
formation of the midbrain, cerebellum, and inferior olivary nuclei of the medulla ob-
longata. Succinic semialdehyde reductase-immunoreactive cells were distributed ex-
tensively in rat brain, especially immunoreactive cells were strongly observed in the areas 
associated with the limbic system and reticular formation. 
y-Aminobutyric acid (GABA) is the major in-
hibitory neurotransmitter in the mammalian central 
nervous system, and more is known about its meta-
bolic pathway than that of the amines, peptides and 
acethylcholine. GABA is mainly produced through en-
zymatic decarboxylation of glutamic acid by glutamic 
acid decarboxylase (GAD); degradation of putrescine 
also yields GABA (Lee and Cho, 1992). The re-
gulation of the metabolic pathways of GABA is com-
plex. The breakdown of GABA occurs through two 
possible pathways, one of which is through the con-
secutive action of two enzymes, GABA-transaminase 
and succinic semialdehyde dehydrogenase, resulting 
in the formation of succinic semialdehyde (SSA) and 
succinate (van Bemmelen et al. , 1985). Succinic semi-
aldehyde dehydrogenase produces succinate, which 
enters the TCA cycle and is converted to glutamate. 
Glutamate is then recycled to GABA through GAD 
(GABA shunt) (Doherty and Roth, 1978). There is 
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another breakdown pathway of GABA in the brain, 
and this involves the synthesis of y-hydroxybutyrate 
(GHB) (Doherty et ai. , 1975; Margolis, 1969). 
GABA transaminase converts GABA to succinic 
semialdehyde, which is subsequently converted to 
GHB by succinic semialdehyde reductase (SSR) (Cho 
et aI. , 1993; Vayer et al. , 1985; 1987). The latter reac-
tion has been the focus of active research, but as of 
yet, the mechanism of the reduction pathway has not 
been established, and the research of the reduction of 
SSA to GHB has not attracted as much interest as 
that of the transamination of GABA to SSA. How-
ever, GHB research is ongoing and one of the results 
has been the discovery of a binding site that has a 
high affinity for GHB on cell membranes that form 
synapses (Benavides et al. , 1982b) and has been stu-
died in the brains of rats and pigs (Hearl and Chur-
The abbreviations used are: GABA, y-aminobutyric acid; 
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chich, 1985; Rivett et ai. , 1981). The synthesis of 
GHB is an important step in the GABA shunt. 
y-Hydroxybutyrate (GHB) is an endogenous meta-
bolite of the mammalian brain (Roth and Giarman, 
1968). It produces CNS depression (sedation), and is 
thus used as a general anesthetic in humans (Laborit 
et ai., 1961; Roth and Giarman, 1968). GHB is 
unevenly distributed in the brain; for example, it is 
found in the hippocampus, cerebellum and dien-
cephalon (Snead and Morley, 1981). SSR is located 
in neurons and nerve endings exclusively (Rumigny 
et ai., 1980). GHB may have a neurophysiological 
role as a putative neurotransmitter (Benavides et ai., 
1982; Maitre and Mandel, 1984). Although the phy-
siological role of GHB is unknown, aldehyde reduc-
tase which produces it has been thought to play a 
scavenging function in the removal of toxic al-
dehydes (Whittle and Turner, 1981). An enzyme that 
seems specific for the conversion of succinic semi-
aldehyde to GHB has been purified and characterized 
in rat, human and bovine brain (Benavides et ai., 
1982; Cash et ai., 1979; Cho et ai., 1993; Rumigny 
et ai. , 1980). This enzyme is a soluble enzyme lo-
cated in the cytosol of neurons, and has an uneven re-
gional distribution in the brain (Rumigny et ai. , 1981). 
Several pathways also have been suggested for GHB 
degradation, such as its conversion into succinic acid 
and other TCA cycle intermediates (Doherty and 
Roth, 1978), interconversion into GABA (Cho et ai., 
1993; Margolis, 1969; Roth and Giarman, 1969), and 
breakdown via ~-oxidation (Walkenstein et ai. , 1964). 
Some evidence indicates that GHB biosynthesis may 
be an important step in the GABA shunt, and that 
GHB may be of pharmacological significance acting as 
an anesthesia, evoking the state of sleep, and increasing 
the brain dopamine level (Hearl and Churchich, 1985; 
Rivett et ai., 1981). Despite many interesting ob-
servations, reduction of SSA to GHB has not received 
due attention, probably because the mechanism by 
which this reductive pathway operates in vivo is not yet 
clearly known. NADPH-dependant SSR was purified to 
apparent homogeneity from bovine brain by several 
chromatographic procedures (Cho et ai., 1993). Mono-
clonal antibodies against bovine brain SSR were pro-
duced and characterized (Choi et ai., 1995). The mAbs, 
which specifically recognized SSR on Western blots, 
were characterized and used as probes for a cross-reac-
tivity study of the brain enzymes from some mam-
malian and an avian species (Choi et ai. , 1995). 
It is with this background that we investigated the 
localization of SSR in rat brain. These results may 
clarify the reduction of SSA to GHB, and aid in un-
derstanding the physiological role of GHB. 
Materials and Methods 
Purification of succinic semiaidehyde reductase 
Succinic semialdehyde reductase from bovine brain 
was purified according to the method of Cho pre-
viously described (Cho et ai. , 1993). During pu-
rification, enzyme activity was assayed in a solution 
containing 0.1 M potassium phosphate (PH 7.2), suc-
cinic semialdehyde (120 11M) and NADPH (50 11M). 
The oxidation of NADPH to NADP+ was measured 
by following the decrease in absorbance at 340 nm 
by the method of Hearl and Churchich (1985). One 
unit of enzyme activity was defined as the amount of 
enzyme required to oxidize 1 I1mol of NADPH per 
min at 25 ·C. Protein concentration was estimated by 
the Bradford procedure with bovine serum albumin 
as a standard (Bradford, 1976). 
Production of monocLonai antibodies against succinic 
semiaidehyde reductase 
Monoclonal antibodies against SSR were made ac-
cording to the method of Choi et al. (1995). Purified 
enzymes described above were denatured by adding 
SDS (final concentration 0.1%) and by heat treatment 
for 1 min at 100 ·C. The denatured protein solution 
was mixed with an equal volume of complete Freund's 
adjuvant by sonication and injected into female 
BALB/c mice (6-8 weeks old). The first injection 
was followed by three booster injections at 3- to 4-
week intervals. 
The fusion experiments were performed as follows 
(Choi and Jeon, 1989; Galfre and Milstein, 1981). 
Three or four days after final injection, spleen was ob-
tained from the animal and was cut into small pieces. 
Prepared spleen and Sp2/0-Ag-14 cell suspensions 
were combined and 1 ml of 50% polyethylene glycol 
1500 in incomplete Dulbecco's modified Eagle's 
medium (DME) was added slowly. The fusion pro-
cess was stopped by adding incomplete DME after 
90 s. Twenty ml of incomplete DME was then added 
slowly for a period of 10 min. Cells were collected 
by centrifugation for 1 min at 650 g, suspended care-
fully in 20 ml of HAT medium (hypoxanthine, am-
inopterin, and thymidine) by swirling, and cen-
trifuged for 1 min at 650 g. The cells were resuspend-
ed in 120 ml of HAT medium and the cell suspen-
sion was transferred into each well of 96-well plates. 
About two weeks after the fusion , cultured su-
pernatants were collected and first screened by im-
munodotblot analysis with purified enzyme as an an-
tigen, and then by Western blot analysis. Positive 
clones, selected by the screening methods, were 
grown in tissue culture flasks (75 cm2) and frozen in 
a liquid nitrogen tank. All positive clones were froz-
en first and cloned by limiting dilution after thawing. 
Immunodot blotting and Western blotting con-
firmed the monoclonal antibodies to be against the pu-
rified enzyme (Towbin et ai. , 1979). 
Tissue preparation for light microscope observation 
The animals were anesthetized by ether and then 
perfused through the left ventricle with saline fol-
lowed by 4% paraformaldehyde (0.1 M phosphate 
buffered saline, PBS, pH 7.4). The midbrain was re-
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moved and placed in a fresh fixative for 4 to 24 h at 
4 °c . Tissues were trimmed according to the atlas of 
Paxinos and Watson (1986). After being dehydrated 
and cleared, they were embedded in paraplast. Tis-
sues were sectioned at 6 11m thickness, and placed on 
a slide treated with gelatin. One tissue section was im-
munohistochemically stained for SSR by using the 
peroxidase-antiperoxidase (PAP) method of Stern-
berger (1986), and the other section was given Nissl 
staining. 
Immunoperoxidase staining 
All tissue sections were immunohistochemically 
stained for the SSR monoclonal antibody by using 
the peroxidase-anti peroxidase (PAP) method of Stern-
berger (1986). Before staining, tissues were pretreated 
in 3% hydrogen peroxide solution for 10 min and sev-
eral rinses in phosphate buffer (PH 7.4, containing 
0.1 % Triton X-100). They were incubated in PBS 
solution containing SSR monoclonal antibody for 72 
h at 4 °c, and washed. They also were incubated with 
goat anti-rabbit gamma globulin (GAR; Chernicon In-
ternational Inc., Temecula, CA, U.S.A.) diluted 1:50 
for 1 h at room temperature. The sections were rinsed 
several times with the same phosphate buffer and 
then placed in peroxidase-antiperoxidase (PAP) con-
jugates (Chemicon International Inc., Temecula, CA, 
U.S.A.) and diluted 1:100 for 1 h at room tem-
perature. Following several rinses in phosphate buffer, 
the sections were placed in 0.05% diaminobenzidine 
(DAB; Sigma Chemical Co., St. Louis, MO, U.S .A.) 
solution containing 0.01% hydrogen peroxide for 10 
min and washed with distilled water. Controls were 
prepared using incubation solution without primary 
antibodies. All incubation steps were performed in a 
humidified chamber. 
Tissue slides were made according to a general tis-
sue preparation procedure. 
Immunocytochemical staining for electron microscopical 
preparation 
For electron-microscopic observation, the animals 
were perfused through the left ventricle with saline 
followed by 3% paraformaldehyde, 3% glutar-
aldehyde, and 0.1 % picric acid in 0.1 M phosphate 
buffer (PH 7.4). 
The tissue was then sectioned on a vibratome at 50 
11m. The free-floating sections were then incubated in 
1 % sodium borohydride in 0.1 M phosphate buffer 
for 30 min followed by a six 5-min rinse in phos-
phate buffer. The sections were exposed to a graded 
series of alcohols (10%, 25%, 40%, 25%, 10%) in 
phosphate buffer for 5 min each to enhance pene-
tration of antibodies while preserving ultrastructural 
detail (Light et ai., 1983). All tissue sections were im-
munocytochemically stained for SSR monoclonal an-
tibody by using the peroxidase-antiperoxidase (PAP) 
method of Sternberger (1986). For electron mi-
croscopy, the immunocytochemically-stained tissue 
was thoroughly rinsed in a phosphate buffer and plac-
ed in 1% osmium tetroxide in 0.1 M phosphate buf-
fer for 30 min. The tissue was then rinsed in a 
maleate buffer (PH 6.0), stained with uranyl acetate 
in maleate buffer, rinsed, dehydrated, and embedded 
with EPON mixture. A selected area was trimmed 
and mounted on an EPON chuck with a drop of 
EPON. The thin sections were cut and mounted on 
the copper grids and viewed without lead citrate stain-
ing with a Philips or Hitachi electron microscope. 
Results and Discussion 
Succinic semialdehyde reductase (SSR) was pu-
rified through FPLC Mono-Q chromatography from 
bovine brain by Cho et al. (1993). We obtained a sin-
gle protein band on an SDS gel, and monoclonal an-
tibodies against bovine brain succinic semialdehyde 
reductase were produced. In order to enhance the im-
munogenicity of the protein, purified enzyme was 
denatured in the presence of SDS and injected into 
animals (Choi et al., 1995). From two fusion ex-
periments, 16 positive clones were initially screened 
by immunodotblot analysis and nine hybridomas out 
of the 16 clones were finally selected. Since the 
monoclonal antibodies recognized SSR from several 
mammalian and an avian species (Choi et al., 1995), 
cross-reactivity of the mAbs with SSR from rat brain 
occurred. 
y-Hydroxybutyrate (GHB) is an endogenous meta-
bolite of the mammalian brain (Giarman, 1970), and 
might play a neurophysiological role act as a putative 
neurotransmitter (Benavides et al., 1982; Maitre and 
Mandel, 1984). An enzyme that seems specific for 
conversion of succinic semialdehyde to GHB has re-
cently been isolated and characterized in rat, human 
and bovine brain (Benavides et al., 1982; Cash et al., 
1979; Cho et al., 1993; Rurnigny et at., 1980). 
Despite the potential significance of SSR, the dis-
tribution of SSR has not yet been established. 
Snead and Morley (1981) investigated the con-
centration of GHB in developing and mature rat, mon-
key, and human brains, together with postmortem 
GHB concentration. They discovered that there is no 
big change in the concentration of GHB after death 
and that GHB is most concentrated in the hy-
pothalamus and cerebral cortex of rats. Also, from 
the 12 to 14th day after birth there is a significant de-
crease in the concentration. Furthermore, Vayer et al. 
(1987), measured the concentration of GHB in the 
mammalian brain using gas chromatography, and re-
ported high concentrations in the hippocampus, cere-
bellum, cerebrum of a guinea pig, and especially in 
the hippocampus of monkeys and the hippocampus, 
thalamus, and the cerebrum of a rat. Relatively low 
concentrations were discovered in the cerebral cortex 
(Snead, 1987). However, most of these results are bas-
ed on measurement of GHB concentrations in tissue, 
and there is still no report of the direct observation of 
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Figure 1. Distribution of the succinic semialdehyde reductase in a rat brain. a) The section through 0.70 mm from the breg-
ma and 9.70 mm from the interaural line. b) The section through - 1.40 mm from the bregma and 7.60 mm from the in-
teraural line. c) The section through - 3.30 mm from the bregma and 5.70 mm from interaural line. d) The section through 
- 5.80 mm from the bregma and 3.20 mm from the interaural line of the midbrain level. e) The section through - 7.64 
from the bregma and 1.36 mm from the interaural line. f) The section through - 10.04 mm from the bregma and - 1.04 
mm from the interaural line. 1-5, cerebellar lobules; 2n, optic nerve; 3V, 3rd ventricle; 3n, oculomotor nerve; 4n, trochlear 
nerve; 4V, 4th ventricle; 7n, facial nerve; 8vn, vestibulocochlear nerve; aca, anterior commissure; AcbC, accumbens nucleus 
core; AD, anterodorsal thalamic nucleus; AF, amygdaloid fissure; AH, anterior hypothalamic area; AM, anteromedial thalam-
ic nucleus; Amg, amygdaloid complex area; APT, anterior pretectal nucleus; Aq, cerebral aqueduct; Arc, arcuate nucleus; 
ATg, anterior tegmental nucleus; A V, anteroventral thalamic nucleus; B, basal nucleus of Mynert; bas, basilar artery; bic, 
brachium of inf. colliculus; BIC, nucleus of inf. colliculus brachium; CC, corpus callosum; cg, cingulum; CG, central gray; 
CL, centrolateral thalamic nucleus; CM, central medial thalamic nucleus; CPu, caudate putamen; ctg, central tegmental tract; 
DA, dorsal hypothalamic area; D3V, dorsal 3rd ventricle; DB, nucleus of diagonal band; DEn, dorsal entopiriform nucleus; 
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the distribution of GHB or its synthesizing enzyme in 
tissue. 
In this paper, we investigated the distribution of 
SSR in rat brain using the anti-succinic semialdehyde 
reductase antibodies. The brain tissues were sectioned 
similarly to those seen in the rat brain atlas of Pax-
inos (1986) and were stained by the immunoperoxi-
dase staining method using monoclonal antibodies. In 
the section through 0.70 mm from the bregma and 
9. 70 mm fro m the interaural line, immunoreactive 
cells were mainly observed in the lateral septal nuclei 
(Figs. 1a and 2a), vertical limb of diagonal band nu-
cleus (Fig. 1a), and ventral pallidum (Fig. 1a). These 
areas belong mainly to the substantia innominata 
(Perry et ai. , 1984). In the section through - 1.40 
mm from the bregma and 7.60 mm from the in-
teraural line (Fig. 1b), immunoreactive cells were 
shown in caudateputamen of the basal ganglia (Fig. 
1b), basal nucleus of Meynert (Fig. 2b), and amyg-
daloid complex (Fig. 1b). And in the paraventricular 
thalamic nucleus (Fig. 1b), reticular thalamic nucleus 
(Fig. 2c) of the thalamus, paraventricular hy-
pothalamic nucleus (Fig. 2e) and supraoptic nucleus 
(Fig. 2f) of the hypothalamus, immunoreactive cells 
were also observed. The reticular thalamic nucleus is 
closely related functionally to the 'sleeping' area 
(Macchi and Bentivoglio, 1986; Steridae and Llinas, 
1988). This area, which receives the afferant fibers 
from most of the thalamic nucleus, and sends the ef-
ferent fibers to the thalamic nucleus, is believed to 
play an important role in neural conduction in the 
thalamus (Russchen et ai., 1987; Steridae and Llinas, 
Figure 1. Continued. 
1988). SSR-immunoreactive cells were found in the 
basal nucleus of Meynert, which also belongs to sub-
stantia innominata. This nucleus is composed of cells 
containing mainly acetylcholine, and has been shown 
to undergo significant changes in Alzheimer's disease 
(Rogers et ai., 1985; Whitehouse et ai., 1982). The 
immunoreactive cells in the basal nucleus of Meynert 
were relatively large. In the section through - 3.30 
mm from the bregma and 5.70 mm from the in-
teraural line, immunoreactive cells were observed 
clearly in some basal ganglia and thalamic areas (Fig. 
1c), especially the globus pallidus (Fig. 2d), reticular 
thalamic nucleus, and ventral posterolateral nucleus 
(Fig. 1c), etc. Immunoreactive cells were also found 
in the hypothalamic area, raphe nuclei, and reticular 
formation. In the section through - 5.80 mm from 
bregma and 3.20 mm from the interaural line of the 
midbrain level (Fig. 1d), there were some areas that 
immunostained against SSR monoclonal antibodies, 
such as dorsal raphe nuclei, median raphe nuclei (Fig. 
1d), the rostal linear raphe nuclei (Fig. 3a), red nu-
cleus (Fig. 3a), substantia nigra (Fig. 3b), inter-
peduncular nucleus (Fig. 1d), etc. These areas are 
also related to the limbic system, especially the dorsal 
raphe, median raphe, dorsal and ventral tegmental nu-
cleus, periaqueductal gray matter, and the inter-
peduncular nucleus, which, combined, constitute the 
'midbrain limbic area' (Robertson and Kaitz, 1981). 
At the level of the inferior colliculus of the midbrain 
(Fig. Ie), immunoreactive cells were also observed in 
the doral and median raphe nuclei (Figs. 3c and Ie), 
anterior tegmental nucleus (Fig. Ie), and reticular for-
OG, dentate gyrus; OMH, dorsomedial hypothalamic nucleus; OpMe, deep mesencephalic nucleus; DR, dorsal raphe nucleus; 
En, entopiriform nucleus; Ent, enrorhinal cortex; EW, Edinger-Westphal nucleus; f, fornix ; Fl, flocculus; Fr, frontal cortex; 
GP, globus pallidus; HC, hippocampus; HOB, nucleus of horizontal limb of diagonal band; ic, internal capsule; IC, inferior 
colliculus; ICj, islands of Calleja; IMO, intermediodorsal thalamic nucleus; IMLF, interstitial nucleus of mlf; JP, in-
terpeduncular nucleus; LC, locus coeruleus; LOOM, laterodorsal thalamic nucleus, dorsomedial; LOVL, laterodorsal thalam-
ic nucleus, ventrolateral; LH, lateral hypothalamic nucleus, II, lateral lemniscus; LP, lateral posterior thalamic nucleus; 
LPMR, lateral posterior thalamic nucleus, mediorostral ; LSD, lateral septal nucleus, dorsal; LSI, lateral septal nucleus, in-
termediate; LSV, lateral septal nucleus, ventral ; LV, lateral ventricle; m5, motor root of trigeminal nerve; MA3, medial ac-
cessory oculomotor nucleus; mcp, middle cerebellar peduncle; MOC, mediodorsal thalamic nucleus, central; MOM, 
mediodorsal thalamic nucleus, medial; MOL, mediodorsal thalamic nucleus, lateral, ME, median eminence; Me5, mesen-
cephalic trigeminal nucleus; mfbb, medial forebrain bundle; MG, medial geniculate body; ml, medial lemniscus; mlf, medial 
longitudinal fasciculus; MnR, median raphe nucleus; Mo5, motor trigeminal nucleus; MPA, medial preoptic area; MS, me-
dial septal nucleus; mt, mammillothalamic tract; MTu, medial tuberal nucleus; NIC, nucleus of inf. colliculus; OC, opt, optic 
tract; OT, nucleus of optic tract, ox, optic chiasm; P5, peritrigeminal zone; PaAP, paraventricular hypothalamic nucleus; Par, 
parietal cortex; PC, paracentral thalamic nucleus; PFl, paraflocculus; Pir, piriform nucleus; PLF, posterolateral fissure; Pn, 
pontine reticular nucleus; PnO, pontine reticular nucleus; Po, posterior thalamic nuclear group; PO, paraolivary nucleus; 
PPTg, pedunculopotine tegmental nucleus; Pr5 , priciple sensory trigeminal nucleus, PrF, primary fissure ; PRh, perirhinal cor-
tex ; PrS, presubiculum; PT, paratenial thalamic nucleus; PYA, paraventricular thalamic nucleus; PVP, paraventricular thalam-
ic nucleus, posterior, py, pyramidal tract; R, red nucleus; Re, reuniens thalamic nucleus; RF, rhinal fissure; RLi, rostral 
linear raphe nucleus; Rmg, raphe magnus nucleus; Rt, reticular thalamic nucleus; RtTg, reticulotegmental nucleus; s5, sen-
sory root of trigeminal nerve; SCh, suprachiasmatic nucleus; SC, sup . colliculus; scp, superior cerebellar peduncle; SHi, sep-
to hippocampal nucleus; SI, substantia innominata; sm, stria medullaris thalami; SNC, substantia nigra compacta; SNL, sub-
stantia nigra lateral ; SNR, substantia nigra reticular, SO, supraoptic nucleus; Subl, subincertal nucleus; Te, temporal cortex; 
Tg, tegmental nucleus; tz, trapezoid body; TZ, nucleus of trapezoid body; VC, ventral cochlear nucleus; YEn, ventral en-
topiriform nucleus; VM, ventromedian thalamic nucleus; VMH, ventromedian hypothalamic nucleus; VP, ventral posterior 
thalamic nucleus; VPM, ventral posteromedial thalamic nucleus; VPL, ventral posterolateral thalamic nucleus; xscp, decus-
sation of sup. cerebellar peduncle; ZI, zona incerta. 
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Figure 2. SSR-immunoreactive cells in the upper brain of a rat. a) Septal nucleus (Sp) (bar=40 !-lm). b) Basal nucleus of 
Meynert (B). Some neuron of the reticular thalamic nucleus (RT) are also observed (bar=80 !-lm). c) Reticular thalamic nu-
cleus (RT). There are many immunoreactive cells in each area (bar=52.6 !-lm). d) Globus pallidus (GP). Immunoreactive 
cells are observed distinctly. The internal capsule (ic) is also shown (bar=105 !-lm). e) Paraventricular hypothalamic nuclei 
(PY) are observed by the 3rd ventricle (3Y) (bar=80 !-lm). f) Neurons of the supraoptic nucleus (SO) are immunostained 
against SSR (bar=80 !-lm) . 





Figure 3. SSR-immunoreactive cells in the brain stem of a rat. a) Immunoreactive cells were observed in a rostral linear 
raphe nucleus (RLi) and red nucleus (R) (bar=105 !-lm). b) Substantia nigra (SN) (bar=80 !-lm). c) dorsal raphe nucleus (DR). 
A cerebral queduct (aq) is also shown (bar=105 !-lm). d) Immunoreactive cells are mainly distributed to mesencephalic tri-
geminal nuclei (Me5), ventral cochlear nuclei (YCA), and pontine reticular nuclei (Pn), and a superior cerebellar peduncle 
(scp) and trigeminal nerve (s5) are also observed (bar=263 !-lm). e) Inferior olivary nucleus, there are many immunoreactive 
cells (bar=263 !-lm). f) Cerebellar cortex, many Purkinje cells are immunostained against SSR (bar=105 !-lm). 
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Figure 4. Electron micrograph of SSR-immunoreactive structures in a rat brain. a) Reticular thalamic nucleus. SSR-im-
munoreactive structures (arrows) are observed around microtubules in the axoplasm of unmyelinated axons (UA) (bar:::1 /-lm). b) 
Dorsal raphe nucleus. SSR-immunoreactive structures (arrows) are also observed within the mitochondrial matrix (bar:::1 11m). 
mation (Fig. I e). This level was sectioned through 
- 7.64 from bregma and 1.36 mm from the interaural 
line. In the section through - 10.04 mm from the 
bregma and - 1.04 mm from the interaural line (Fig. 
It), immunoreactive cells were found mainly in the 
mesencephalic trigeminal nucleus (Fig. 3d), ventral 
cochlear nucleus (Fig. 3d), pontine reticular nucleus 
(Fig. 3d), and inferior olivary nucleus complex (Fig. 
3e) of the brain stem, and were also observed in the 
dentate nucleus of the cerebellum (Fig. It) and the 
cerebellar cortex, especially in Purkinje cells (Fig. 3t). 
These results partly coincided with other biochemical 
studies (Hechler et al., 1987; 1992; Snead, 1987). 
Hechler et al. (1987) investigated the regional dis-
tribution of high-affinity y-eH]hydroxybutyrate bind-
ing sites, which were absent in the caudal parts of the 
brain (cerebellum, pons, and medulla). According to 
these results, SSR-immunoreactive cells are widely 
distributed in the CNS in areas such as the inferior 
olivary complex, medulla oblongata, and the cere-
bellum. 
Observations through the electron microscope re-
vealed SSR-immunoreactive particles in the axoplasm. 
The positive structures were found mainly around mi-
crotubules in the axoplasm, and within the mi-
tochondrial matrix. In unmyelinated nerve fibers, high 
electron dense positive materials were also observed 
around the micro tubules (Fig. 4a) and in the mi-
tochondrial matrix (Fig. 4b). SSR is a hydrophilic en-
zyme that is present mainly in the cytoplasm of neu-
rons, and has been reported to not be evenly dis-
tributed in the brain (Rumigny et ai., 1981). However, 
SSR-immunoreactive particles were found not only in 
the axoplasm, but also within the mitochondrial ma-
trix. 
Succinic semialdehyde reductase-immunoreactive 
cells were distributed extensively in rat brain, and 
were observed particularly in the areas associated 
with the limbic system and reticular formation. We 
identified the presence of a specific enzyme as-
sociated with the reduction of SSA to GHB in rat 
brain by immunoperoxidase staining using mAbs 
against SSR. These results were associated with the 
function of y-hydroxybutyrate, which is the pro-
duction of CNS depression (sedation), and it is used 
as a general anesthetic for humans. 
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